title: Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration.
abstract: OBJECTIVE
  To report on the development of retinal pigment epithelium tears after intravitreal injections of bevacizumab as treatment of exudative age-related macular degeneration (AMD).
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  The study included 63 patients who received an intravitreal injection of 1.5 mg bevacizumab as treatment of a detachment of the retinal pigment epithelium attributable to AMD and who had a follow-up of at least two months.
  
  
  RESULTS
  Four patients (6%) developed a tear of the retinal pigment epithelium in the parafoveal region. Compared with the baseline value, visual acuity at the end of follow-up remained stable in three patients and declined in the fourth patient.
  
  
  CONCLUSIONS
  Intravitreal injections of bevacizumab may be followed by a tear of the retinal pigment epithelium in eyes with exudative AMD and a retinal pigment epithelium detachment.
authors.affiliation: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Ulrich.Spandu@augen.ma.uni-heidelberg.de
authors.forename: Ulrich H M
authors.initials: UH
authors.lastname: Spandau
authors.forename: Jost B
authors.initials: JB
authors.lastname: Jonas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab